US basedUS hosted
Desks
$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves First At-Home Treatment for Agitation

The FDA has approved IGALMI (dexmedetomidine) sublingual film for at-home use, Teva Pharmaceuticals announced on Monday, November 16, making it the first approved treatment patients can take at home for agitation tied to schizophrenia, schizoaffective disorder or bipolar I or II disorder.

A Teva factory in Petah Tikva, Israel (archive). Photo: Shlomo Katzav, CC BY-SA 4.0, via Wikimedia Commons.
Summary

The approval moves a supervised emergency treatment into the home, on a safety trial of 102 patients and 1,160 episodes. Teva hasn't said what it will charge or when the at-home version reaches pharmacies. Both answers decide how much this changes.

Tap a passage. React to the part that matters.

The U.S. Food and Drug Administration has approved IGALMI (dexmedetomidine) sublingual film for at-home use, Teva Pharmaceuticals announced on Monday, November 16. It's the first FDA-approved treatment that can be used at home for acute agitation associated with schizophrenia, schizoaffective disorder or bipolar I or II disorder in adults. Until now, the same drug was approved only under a healthcare provider's supervision.

The mechanism is a film that dissolves under the tongue. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, a sedative class long used in hospital settings. The sublingual film turns that hospital mechanism into a dose a patient can take without an injection, a clinician or an emergency room. That's the operational change inside the approval: the setting moves, and the supervision requirement goes with it.

The evidence is the Phase 3 SERENITY At-Home trial, a randomized, double-blind, placebo-controlled, 12-week safety and tolerability study. In it, 1,160 agitation episodes in 102 patients were treated with IGALMI, and the trial met its primary endpoint of safety and tolerability in the home setting. Tolerability stayed consistent with repeat dosing across the 12 weeks, and no patient stopped treatment because of tolerability, Teva said.

The side-effect profile is the one the label already carries. The most common adverse events, reported in at least 5% of patients and more often than with placebo, were somnolence, dry mouth, dizziness and numbness or tingling in the mouth. Those are manageable effects in a clinic. The trial's job was to show they stay manageable when the person taking the film is agitated, at home and alone with the dose.

The paperwork trail runs through three owners and one earlier approval. IGALMI was first approved in April 2022 for supervised use. The at-home application was filed on January 14, 2026 as a supplemental New Drug Application. BioXcel Therapeutics, the drug's originator, sold nearly all its assets, including IGALMI, to Teva, which completed the acquisition in late October 2026 — weeks before the approval it now owns.

What Teva hasn't announced is the commercial part: no price, no launch date, no pharmacy plan. It said it will announce commercialization plans for at-home use at a later date. For patients whose agitation episodes currently end in an emergency department, the approval is the first legal route to treating an episode where it happens. Whether that route is stocked and priced within reach is the part of the story still unwritten.

The supervised version's history explains why the setting matters. IGALMI's original approval covered agitation episodes in healthcare settings, where a clinician could watch blood pressure and sedation after the dose. Agitation episodes don't schedule themselves around clinic visits, though. They happen at home, at night, and the previous options were a trip to an emergency department or no approved treatment at all. Teva's statement makes that point directly: the approval expands the drug to outpatient settings without a healthcare provider's supervision, where no FDA-approved options were available. The trial's 102 patients treated 1,160 episodes in that real-world setting, which is the entire basis on which the FDA was willing to move the drug out of the clinic.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.